Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioma, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, low grade glioma, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neuroepithelial neoplasm, neurofibroma, neurofibromatosis, neurofibromatosis type 1, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, plexiform neurofibroma, primitive neuroectodermal tumor	Active, not recruiting	Phase 2	2026-04-24		NCT03363217

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
CHU de Quebec-Universite Laval	54
Montreal Children's Hospital of the MUHC	11
St. Justine's Hospital	39

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Alberta Children's Hospital	Calgary	Canada	70
Children and Women's Health Centre of British Colombia	Vancouver	Canada	1
CHU de Québec	Québec	Canada	1
CHU Sainte-Justine	Montreal	Canada	36
IWK Health Centre	Halifax	Canada	7
Montreal Children's Hospital	Montreal	Canada	13
The Hospital For Sick Children	Toronto	Canada	94